Stoke Therapeutics, Inc. $STOK Shares Bought by BVF Inc. IL

BVF Inc. IL grew its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 36.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,265,674 shares of the company’s stock after purchasing an additional 608,578 shares during the period. Stoke Therapeutics accounts for 2.4% of BVF Inc. IL’s portfolio, making the stock its 12th biggest position. BVF Inc. IL’s holdings in Stoke Therapeutics were worth $71,912,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after purchasing an additional 1,149 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the period. Jane Street Group LLC raised its holdings in shares of Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock worth $179,000 after purchasing an additional 15,001 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Stoke Therapeutics by 26.6% during the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock worth $291,000 after purchasing an additional 5,398 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Stoke Therapeutics by 33.9% during the second quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock worth $754,000 after purchasing an additional 16,820 shares during the period.

Insider Activity

In other news, insider Barry Ticho sold 1,795 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the transaction, the insider directly owned 34,826 shares in the company, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on STOK. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Wedbush upped their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Wolfe Research began coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Trading Up 3.8%

Shares of NASDAQ STOK opened at $30.26 on Thursday. The stock has a 50 day simple moving average of $32.07 and a 200-day simple moving average of $32.35. The company has a market cap of $1.88 billion, a PE ratio of -10.77 and a beta of 1.17. Stoke Therapeutics, Inc. has a 12-month low of $11.17 and a 12-month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.01. The business had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. Sell-side analysts forecast that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.